X-ZELL

X-ZELL

Private
Singapore, Central SingaporeHealthcare & Life Scienceshttps://www.x-zell.com

Last Round

Grant

Nov 18, 2020

Total Funding Raised

$4.17M

Momentum Score

25 /100

Company Overview

X-ZELL is a medical technology company that specializes in rare cell detection for early cancer diagnosis. The company has developed a platform technology that isolates, digitizes, and analyzes atypical cells from small blood samples. This system is designed to be integrated into standard laboratory workflows, enabling medical professionals to detect malignant cells, such as tumour-associated Circulating Endothelial Cells (tCEC), with high clarity. By reducing the time from sample to diagnosis, X-ZELL aims to make cancer screening more accessible, affordable, and accurate, with a mission to enable same-day diagnoses from minimally invasive body liquids. The company's initial focus is on a blood test for the early detection of clinically significant prostate cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotech Equipment, Medical Devices, Precision Medicine, Biotechnology, Medical Imaging

Business Model

B2B

Customer Profile

Hardware Sales, Usage-Based SaaS, Government Contracts

AI Layer

Non-AI

Keywords

liquid biopsyearly cancer detectionnext-generation cytologydiagnostic equipmentrare cell detectioncytology platformcell separation technologydigital microscopymedtechoncology diagnosticsminimally invasive diagnosticsprostate cancer testSoftware as a Medical DeviceSaMDimmunofluorescence staining

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

X-ZELL Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

X-ZELL Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
GrantNov 18, 2020
SeedOct 15, 2020

Key People

Founding team and executive leadership

Johannes Hille

Chief Executive Officer (CEO)

Executive Team

Sebastian C. P. Bhakdi

CEO, Group CEO

Executive Team

X-ZELL Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 1, 2026

    Commercial launch of Cryophore multiplex antibody panels on March 1, 2026.

X-ZELL Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

X-ZELL Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about X-ZELL's valuation, stock price, and market status.

Firmographic Details

HeadquartersSingapore, Central Singapore
Employee Range23
Year Founded2014
Last FundingNov 18, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.